Advertisement

Neurochemical Journal

, Volume 13, Issue 3, pp 256–267 | Cite as

The Effect of 3-Hydroxypyridine and Succinic Acid Derivatives on the Activity of Monoamine Oxidases in the Brain Cortex of Rats with Alloxan-Induced Diabetes

  • I. A. VolchegorskiiEmail author
  • A. I. Sinitskii
  • I. Yu. Miroshnichenko
  • L. M. Rassokhina
EXPERIMENTAL ARTICLES
  • 21 Downloads

Abstract—We studied the effects of original Russian 3-hydroxypyridine and succinic acid derivatives (emoxypine, reamberin, and mexidol) on the dynamics of activity of monoamine oxidases (МАО-А and МАО-B) and correlated them to the levels of biogenic amines (serotonin and dopamine) in the brain cortex during the first 2 weeks of alloxan-induced diabetes in rats. An injection of 3-hydroxypyridine derivatives for 7 or 14 days (emoxypine and mexidol) to the alloxan-induced diabetic rats at doses that are equivalent to the treatment range in humans prevented an increase in the activity of cortical МАО-А and dopamine deficiency. The strengths of the effects of emoxypine and mexidol were comparable to the effect of the reference agent α‑lipoic acid. The isolated succinic acid derivative (reamberin) attenuated the activity of МАО-А in the neocortex of rats with alloxan-induced diabetes but caused a transient decrease in cortical serotonin and dopamine levels at the early stages of experiments and failed to correct dopamine deficiency by the end of experiments. A course of injection of the studied drugs for 7 and 14 days increased cortical МАО-B activity; this increase was not associated with a parallel shifts in monoamine levels in the brain cortex of rats with alloxan diabetes. The changes in the activity of cortical МАО that were induced by the drugs were not associated with their effect on the level of circulating corticosterone and hyperglycemia in rats with alloxan-induced diabetes.

Keywords:

alloxan diabetes brain cortex monoamine oxidases A and B serotonin dopamine 3-hydroxypyridine and succinic acid derivatives 

Notes

FUNDING

This study was performed within the framework of the State Task on Research and Development Pharmacophysiology and Biochemical Pharmacology of 3-Hydroxypyridine and Succinic Acid Derivatives (State Registration: АААА-А18-118021890008-4. Registration date: February 18, 2018).

COMPLIANCE WITH ETHICAL STANDARDS

Conflict of interest. The authors declared no conflicts of interest.

Ethical approval. This study was performed in compliance with the Russian and International Ethical Principles and Guidelines for Experiments with Animals [22].

REFERENCES

  1. 1.
    Duncan, J.W., Johnson, S., and Ou, X.M., Drug Disc. Ther., 2012, vol. 6, no. 3, pp. 112–122.Google Scholar
  2. 2.
    Bortolato, M., Chen, K., and Shih, J.C., Adv. Drug Del. Rev., 2008, vol. 60, nos. 13–14, pp. 1527–1533.CrossRefGoogle Scholar
  3. 3.
    Gorkin, V.Z., in Aminoksidazy i ikh znachenie v meditsine (Amine Oxidases and theirIimportance in Medicine), Moscow: Meditsina, 1981.Google Scholar
  4. 4.
    Harro, J. and Oreland, L., Progr. Neuro-Psychopharmacol. Biol. Psychiatry, 2016, vol. 69, pp. 101–111.CrossRefGoogle Scholar
  5. 5.
    Youdim, M.B.H., Edmondson, D., and Tipton, K.F., Nat. Rev. Neurosci., 2006, vol. 7, no. 4, p. 295.CrossRefPubMedGoogle Scholar
  6. 6.
    Goldstein, B.J., Mahadev, K., and Wu, X., Diabetes, 2005, vol. 54, no. 2, pp. 311–321.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kleinridders, A., Cai, W., Cappellucci, L., Ghazarian, A., Collins, W.R., Vienberg, S.G., Pothos, E.N., and Kahn, C.R., Proc. Natl. Acad. Sci. U.S.A., 2015, vol. 12, no. 11, pp. 3463–3468.CrossRefGoogle Scholar
  8. 8.
    Chen, K., Ou, X.M., Wu, J.B., and Shih, J.C., Mol. Pharmacol., 2011, vol. 79, no. 2, pp. 308–317.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Duncan, J.W., Zhang, X., Wang, N., Johnson, S., Harris, S., Udemgba, C., Ou, X.M., Youdim, M.B.H., Stockmeier, C.A., and Wang, J.M., Neuropharmacology, 2016, vol. 105, pp. 329–340.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Volchegorskii, I.A., Shemyakov, S.E., Turygin, V.V., and Malinovskaya, N.V., Bull. Eksp. Biol. Med., 2001, vol. 132, no. 8, pp. 174–177.Google Scholar
  11. 11.
    Kodl, C.T. and Seaquist, E.R., Endocr. Rev., 2008, vol. 29, no. 4, pp. 494–511.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Volchegorskii, I.A., Moskvicheva, M.G., and Chashchina, E.N., Zhurn. Nevrol. i Psikhiatr. im. S.S. Korsakova, 2005, vol. 105, no. 2, pp. 41–45.Google Scholar
  13. 13.
    Volchegorskii, I.A. and Mester, N.V., Klin. Med., 2007, vol. 85, no. 2, pp. 40–45.Google Scholar
  14. 14.
    Volchegorskii, I.A., Miroshnichenko, I.Yu., Rassokhina, L.M., Faizullin, R.M., Malkin, M.P., Pryakhina, K.E., and Kalugina, A.V., Eksp. Klin. Farmakol., 2014, vol. 77, no. 4, pp. 14–20.PubMedGoogle Scholar
  15. 15.
    Volchegorskii, I.A., Rassokhina, L.M., Miroshnichenko, I.Yu., Mester, K.M., Novoselov, P.N., and Astakhova, T.V., Bull. Eksp. Biol. Med., 2010, vol. 150, no. 9, pp. 295–301.Google Scholar
  16. 16.
    Volchegorskii, I.A., Miroshnichenko, I.Yu., Rassokhina, L.M., Faizullin, R.M., and Pryakhina, K.E., Ros. Fiziol. Zhurn. im. I.M. Sechenova, 2016, vol. 102, no. 11, pp. 1312–1322.Google Scholar
  17. 17.
    Volchegorskii, I.A., Sinitskii, A.I., Miroshnichenko, I.Yu., and Rassokhina, L.M., Khim.-Farm. Zh., 2018, vol. 52, no. 1, pp. 3–7.Google Scholar
  18. 18.
    Nestler, E.J., Hyman, S.E., and Malenka, R.C., Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, New York: McGraw-Hill, 2001.Google Scholar
  19. 19.
    Volchegorskii, I.A., Rassokhina, L.M., and Miroshnichenko, I.Yu., Zhurn. Nevrol. Psikhiatr. im. S.S. Korsakova, 2013, vol. 113, no. 6, pp. 50–61.Google Scholar
  20. 20.
    Volchegorskii, I.A., Miroshnichenko, I.Yu., Rassokhina, L.M., Malkin, M.P., Faizullin, R.M., Pryakhina, K.E., and Kalugina, A.V., Zhurn. Nevrol. Psikhiatr. im. S.S. Korsakova, 2015, vol. 115, no. 2, pp. 48–52.Google Scholar
  21. 21.
    Volchegorskii, I.A., Miroshnichenko, I.Yu., Rassokhina, L.M., and Faizullin, R.M., Zhurn. Nevrol. Psikhiatr. im. S.S. Korsakova, 2016, vol. 116, no. 6, pp. 53–59.Google Scholar
  22. 22.
    Mironov, A.N., Bunyatyan, N.D., Vasil’ev, A.N., Verstakova, O.L., Zhuravleva, M.V., Lepakhin, V.K., Korobov, N.V., Merkulov, V.A., Orekhov, S.N., Sakaeva, I.V., Uteshev, D.B., and Yavorskii, A.N., in Rukovodstvo po provedeniyu doklinicheskikh issledovanii lekarstvennykh sredstv (Manual on Preclinical Studies on Medications), Moscow: Grif i K, 2012.Google Scholar
  23. 23.
    Lenzen, S., Diabetologia, 2008, vol. 51, pp. 216–226.CrossRefPubMedGoogle Scholar
  24. 24.
    Volchegorskii, I.A., Dolgushin, I.I., Kolesnikov, O.L., and Tseilikman, V.E., in Eksperimental’noe modelirovanie i laboratornaya otsenka adaptatsionnykh reaktsii organizma (Experimental Modelling and Laboratory Evaluation of Adaptive Responses of the Body), Chelyabinsk: Izdatel’stvo ChGPU, 2000.Google Scholar
  25. 25.
    Rassokhina, L.M., Extended Abstract of Doctoral (Med.) Dissertation, Chelyabinsk: YuUGMU, 2014.Google Scholar
  26. 26.
    De Moor, P., Osinski, P., Deckx, R., and Steeno, O., Clin. Chim. Acta, 1962, vol. 7, no. 4, pp. 475–480.CrossRefPubMedGoogle Scholar
  27. 27.
    Balashov, Yu.G., Fiziol. Zh. SSSR, 1990, no. 12, pp. 280–283.Google Scholar
  28. 28.
    Glowinski, J. and Iversen, L.L., J. Neurochem., 1966, vol. 13, pp. 655–669.CrossRefPubMedGoogle Scholar
  29. 29.
    Huang, G., Zhu, F., Chen, Y., Chen, S., Liu, Z., Li, X., Gan, L., Zhang, L., and Yu, Y., Anal. Biochem., 2016, vol. 512, pp. 18–25.CrossRefPubMedGoogle Scholar
  30. 30.
    Kamyshnikov, V.S., Spravochnik po kliniko-biokhimi-cheskim issledovaniyam i laboratornoi diagnostike (Guide on Clinical Biochemical Studies and Laboratory Diagnostics), Moscow: MEDpress-inform, 2009.Google Scholar
  31. 31.
    Kolb, V.G. and Kamyshnikov, V.S., Spravochnik po klinicheskoi khimii (Guide on Clinical Chemistry), Minsk: Belarus’, 1982.Google Scholar
  32. 32.
    Matlina, E.Sh. and Men’shikov, V.V., Klinicheskaya biokhimiya katekholaminov (Clinical Biochemistry of Catecholamines), Moscow: Meditsina, 1967.Google Scholar
  33. 33.
    Loboda, E.B. and Makarov, Yu.P., Lab. Delo, 1974, no. 4, pp. 219–221.Google Scholar
  34. 34.
    Volchegorskii, I.A., Rassokhina, L.M., and Miroshnichenko, I.Yu., Ros. Fiziol. Zhurn. im. I.M. Sechenova, 2013, vol. 99, no. 4, pp. 491–500.Google Scholar
  35. 35.
    Volchegorskii, I.A., Kolesnikov, O.L., Tseilikman, V.E., Kolesnikova, A.A., and Vladimirov, A.Yu., Probl. Endokrinol., 1997, vol. 43, no. 2, pp. 38–41.CrossRefGoogle Scholar
  36. 36.
    Lavergne, F. and Jay, T.M., Front. Neurosci., 2010, vol. 4, p. 192.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Volchegorskii, I.A., Moskvicheva, M.G., and Chashchina, E.N., Klin. Med., 2004, vol. 82, no. 11, pp. 31–35.Google Scholar
  38. 38.
    Iwakami, S., Misu, H., Takeda, T., Sugimori, M., Matsugo, S., Kaneko, S., and Takamura, T., PLoS One, 2011, vol. 6, no. 11, p. e27401.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Konradi, C., Riederer, P., and Youdim, M.B.H., J. Neur. Trans. Suppl., 1986, vol. 22, pp. 61–73.Google Scholar
  40. 40.
    Voronina, T.A., Farmateka, 2009, no. 6, pp. 35–38.Google Scholar
  41. 41.
    Volchegorskii, I.A., Miroshnichenko, I.Yu., and Rassokhina, L.M., Ros. Fiziol. Zhurn. im. I.M. Sechenova, 2017, vol. 103, no. 7, pp. 755–767.Google Scholar
  42. 42.
    Volchegorskii, I.A., Miroshnichenko, I.Yu., Rassokhina, L.M., and Faizullin, R.M., Eksp. Klin. Farmakol., 2013, vol. 76, no. 7, pp. 6–10.PubMedGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2019

Authors and Affiliations

  • I. A. Volchegorskii
    • 1
    Email author
  • A. I. Sinitskii
    • 1
  • I. Yu. Miroshnichenko
    • 1
  • L. M. Rassokhina
    • 1
  1. 1.South Ural State Medical UniversityChelyabinskRussia

Personalised recommendations